Dailypharm Live Search Close

Delstrigo seeks reimbursement to join the HIV drug market

By Eo, Yun-Ho | translator Byun Kyung A

21.02.04 16:45:00

°¡³ª´Ù¶ó 0
Clinical trial confirms non-inferior efficacy against EFV-FTC-TDF

Industry reports the drug submitted application in December for the once-daily oral combination drug as a first-line therapy


MSD¡¯s HIV new drug Delstrigo has started the National Health Insurance (NHI) reimbursement application process.

The pharmaceutical industry reported, MSD Korea has submitted an application for the NHI reimbursement on an once-daily fixed-dose combination tablet Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) treating human immunodeficiency virus type 1 (HIV-1).

The South Korean authority approved Delstrigo as a treatment for HIV-1 infection in adults with no prior antiretroviral treatment experience.

One of the combined agents, doravirine received South Korea¡¯s Ministry of Food and Drug Safety (MFDS) approval as of Nov. 22, 2019, with a brand name

Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)